- Home
- CTOS vs GYRE Comparison
CTOS vs GYRE Comparison
Compare CTOS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOS
- GYRE
- Stock Information
- Founded
- CTOS 1988
- GYRE 2002
- Country
- CTOS United States
- GYRE United States
- Employees
- CTOS N/A
- GYRE N/A
- Industry
- CTOS Diversified Commercial Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CTOS Consumer Discretionary
- GYRE Health Care
- Exchange
- CTOS Nasdaq
- GYRE Nasdaq
- Market Cap
- CTOS 1.1B
- GYRE 897.1M
- IPO Year
- CTOS N/A
- GYRE N/A
- Fundamental
- Price
- CTOS $5.00
- GYRE $7.42
- Analyst Decision
- CTOS Hold
- GYRE
- Analyst Count
- CTOS 3
- GYRE 0
- Target Price
- CTOS $5.33
- GYRE N/A
- AVG Volume (30 Days)
- CTOS 538.6K
- GYRE 253.7K
- Earning Date
- CTOS 07-31-2025
- GYRE 08-12-2025
- Dividend Yield
- CTOS N/A
- GYRE N/A
- EPS Growth
- CTOS N/A
- GYRE N/A
- EPS
- CTOS N/A
- GYRE 0.02
- Revenue
- CTOS $1,813,205,000.00
- GYRE $100,643,000.00
- Revenue This Year
- CTOS $11.08
- GYRE $21.04
- Revenue Next Year
- CTOS $5.69
- GYRE $89.64
- P/E Ratio
- CTOS N/A
- GYRE $93.77
- Revenue Growth
- CTOS N/A
- GYRE N/A
- 52 Week Low
- CTOS $3.03
- GYRE $6.11
- 52 Week High
- CTOS $6.11
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- CTOS 67.97
- GYRE 39.71
- Support Level
- CTOS $4.63
- GYRE $7.26
- Resistance Level
- CTOS $5.05
- GYRE $8.00
- Average True Range (ATR)
- CTOS 0.16
- GYRE 0.49
- MACD
- CTOS 0.03
- GYRE -0.07
- Stochastic Oscillator
- CTOS 83.33
- GYRE 10.36
About CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.